newsfilter
← Latest News
GlobeNewswire·

Decoy Therapeutics Provides Third Quarter 2026 Business Update

Lead pan-coronavirus program expected to file CTA/IND in 2H 2027Optimized lead candidate shows potential for once-weekly dosing in preclinical studiesCash on balance sheet of $8.1 million at September 30, 2026